ADR Biomedical Holdings Inc.
ADR Biomedical Holdings Inc. Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)
Due to establishment of domestic mass-production systems and the full-scale commercial launch of the Celuration centrifuge and Celuration cell therapy kits, interim sales for the fiscal year ending March 2027 increased to 66 million yen, up 262.7% year-over-year. Operating loss was 311 million yen, and interim net loss attributable to owners of parent was 224 million yen. Full-year earnings guidance is maintained, and the start of insurance coverage for the cell therapy kits is expected to contribute to future performance. Financial condition remains at risk of insolvency, with material uncertainty regarding the assumption of going concern. Measures including domestic production progress, expansion into new fields, and cost reductions are being implemented.
Key Figures
- Net Sales: 66 million yen (Up 262.7% year-over-year)
- Interim Net Loss Attributable to Owners of Parent: -224 million yen
- Total Assets: 272 million yen
- Equity Ratio: 6.0%
- Short-term Borrowings: 370,000 yen
AI要約
Overview of Performance
Interim net sales rose substantially to 66 million yen (up 262.7% year-over-year), while operating loss remained at 311 million yen and ordinary loss at 315 million yen, keeping the company in a deficit position. Full-scale commercial sales of the newly launched Celuration cell therapy kits are expected to contribute from the second half of fiscal 2027, and progress is being made in establishing domestic mass-production systems for key products. The full-year forecast is unchanged, but material uncertainty regarding the assumption of going concern is disclosed.
Financial Position and Capital Policy
The financial position shows total assets of 272 million yen and net assets of -202 million yen, indicating continued negative net assets; current liabilities amount to 463 million yen, driven in part by increased short-term borrowings. As of November 13, 2026, measures to stabilize cash flow were decided, including HG Capital's debt waiver of 400 million yen and maintenance of a commitment line up to 500 million yen as financial support. Material uncertainty regarding the assumption of going concern continues to be disclosed.
ADR Biomedical Holdings Inc.
Company overview · Stock price · Financial data · All IR